Update on neoadjuvant/preoperative therapy of breast cancer: Experiences from the German Breast Group

Current Opinion in Obstetrics and Gynecology

Volumn 25, Issue 1, 2013, Pages 66-73

  Von Minckwitz, Gunter ^a   Untch, Michael ^b   Loibl, Sibylle ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

bevacizumab; breast cancer; lapatinib; neoadjuvant treatment; pathological complete response; pertuzumab; trastuzumab; trastuzumab emtansine

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; LAPATINIB; PERTUZUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84873082630     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835c0889     Document Type: Review

References (17)

1. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-1804.
2. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2011; 22:1736-1747.
3. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26:778-785.
4. Kaufmann M, Eiermann W, Schü tte M, et al. Long term results form the neoadjuvant GeparDuo trial comparing a dose-dense regimen of adriamycin and docetaxel (ADoc) with a standard regimen of adriamycin/cyclophosphamide followed by docetaxel (AC-Doc) in patients (pts) with operable breast cancer (BC). J Clin Oncol 2010; 28 (15s):76s. (Suppl; abstr 537).
5. von Minckwitz G, Blohmer JU, Costa SD, et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients: results of the GeparTrio trial. Cancer Res 2011; 71 (Suppl 24):103s.
6. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377-384.
7. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-144.
8. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25-32.
9. von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
10. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-214.
11. O'Shaughnessy J, Schwartzberg MA, Danso HS, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29(Suppl):abstr 1007.
12. Llombard A, Lluch A, Villanueva C, et al. SOLTI NeoPARP: a phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC). J Clin Oncol 2012; 30(Suppl):abstr 1011.
13. Gerber B, Eidtman H, Rezai M, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: secondary endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol 2011; 29(Suppl):abstr 1006.
14. von Minckwitz G, Mü ller B, Blohmer JU, et al. Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: results of the GeparTrio trial. J Clin Oncol 2012; 30(Suppl):abstr 1023.
15. von Minckwitz G, Kummel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100:552-562.
16. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbinecapecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100:542-551.
17. von Minckwitz G, Kaufmann M, Kümmel S, et al. Local recurrence risk after neoadjuvant chemotherapy. Pooled analysis on 5477 breast cancer patients. Cancer Res 2011; 71 (Suppl 24):142s.